Huang, Sicong
Kronzer, Vanessa L.
Dellaripa, Paul F.
Deane, Kevin D.
Bolster, Marcy B.
Nagaraja, Vivek
Khanna, Dinesh
Doyle, Tracy J.
Sparks, Jeffrey A.
Funding for this research was provided by:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (K24 AR063120-07, R01AR07047)
National Institutes of Health (K23 HL119558, R03 HL148484, K23 AR069688, K23 HL119558, R03 AR075886, L30 AR066953, P30 AR070253, P30 AR072577)
Rheumatology Research Foundation (K supplement)
R. Bruce and Joan M. Mickey Research Scholar Fund
Article History
First Online: 1 September 2020
Compliance with Ethical Standards
:
: Dr. Dellaripa reports involvement in a clinical trial funded by Genentech and a study funded by Bristol-Myers Squibb. Dr. Bolster reports clinical trial funding from Cumberland and Corbus; is a consultant to Gilead Sciences; and has stock ownership in Johnson and Johnson. Dr. Khanna is a consultant to Acceleron, Actelion, Amgen, Bayer, Boehringer Ingelheim, CSL Behring, Corbus, Galapagos, Genentech/Roche, GSK, Gilead, Horizon Merck, Mitsubishi Tanabe Pharma, Regeneron, Sanofi-Aventis, and United Therapeutics; and holds stocks in Eicos Sciences, Inc. Dr. Doyle reports research funding from Bristol-Myers Squibb and involvement in a clinical trial funded by Genentech and Bristol-Myers Squibb. Dr. Sparks reports research funding from Bristol-Myers Squibb and Amgen and consultancy to Bristol-Myers Squibb, Gilead, Inova, Janssen, and Optum.
: This article does not contain any primary data of human or animal subjects performed by any of the authors.
: The funders had no role in the decision to publish or preparation of the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard University, its affiliated academic health care centers, or the National Institutes of Health.